Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application
saxagliptin tablets, 2.5mg and 5mg. Aurobindo Pharma’s saxagliptin tablets are an AB-rated generic equivalent to the reference listed drug (RLD), Onglyza Tablets, manufactured by AstraZeneca AB.
Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
Saxagliptin tablets has an estimated market size of US $104.7 million for the twelve months ending May 2023, as per IQVIA.
